945663-27-4

Upstream product

• 4549-32-0 1,8-dibromooctane 
• 18239-10-6 2,4-dihydroxy-4'-chlorobenzophenone 
• 122-01-0 4-chloro-benzoyl chloride 
• 85-28-9 2-hydroxy-4-methoxy-4'-chlorobenzophenone 
• 57600-76-7 4-chloro-2',4'-dimethoxybenzophenone 
• 151-10-0 1,3-Dimethoxybenzene 

Downstream Products

• 945663-30-9 (E)-(4-(4-bromobut-2-enyloxy)-2-hydroxyphenyl)(4-chlorophenyl)methanone 
• 945663-32-1 (E)(4-(4-(3-bromopropoxy)but-2-enyloxy)-2-hydroxyphenyl)(4-chlorophenyl)methanone 
• 945663-31-0 (E)-(4-chlorophenyl)(2-hydroxy-4-(4-(3-hydroxypropoxy)but-2-enyloxy)phenyl)methanone 

Relevant academic research and scientific papers

Discovery of 1,4-didydroxy-2-naphthoate prenyltransferase inhibitors: New drug leads for multidrug-resistant gram-positive pathogens

Since utilization of menaquinone in the electron transport system is a characteristic of Gram-positive organisms, the 1,4-dihydroxy-2-naphthoate prenyltransferase (MenA) inhibitors 1a and 2a act as selective antibacterial agents against organisms such as methicillin-resistant Stapylococcus aureus (MRSA), Staphylococcus epidermidis (MRSE), and Mycobacterium spp. Growth of drug-resistant Gram-positive organisms was sensitive to the MenA inhibitors, indicating that menaquinone synthesis is a valid new drug target in Gram-positive organisms.

COMPOSITIONS AND METHODS OF USE OF ELECTRON TRANSPORT SYSTEM INHIBITORS

The invention provides compounds of the formula: or a pharmaceutically acceptable salt thereof, where m, n, R1, R2, R3 R4, R5, R6, R7 are those defined herein. The invention also provides pharmaceutical compositions comprising a compound of the invention, methods for using compounds and/or pharmaceutical compositions of the invention, and methods for synthesizing compounds of the invention.